Cowen Starts 22nd Century Group (XXII) at Outperform
Get Alerts XXII Hot Sheet
Rating Summary:
2 Buy, 2 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 1 | Down: 4 | New: 14
Join SI Premium – FREE
Cowen analyst Vivien Azer initiates coverage on 22nd Century Group (NYSE: XXII) with a Outperform rating and a price target of $5.00.
The analyst comments "We initiate coverage of XXII with an Outperform rating. As a leader in plant genetics, XXII is positioned to capitalized on major near-term commercialization catalysts including potential FDA MRTP designation for its VLN cigarettes and the monetization of its biosynthesis IP starting in 2H21 as well as longer term tobacco regulatory tailwinds. Our $5 PT assumes a 10x FY2 revenue multiple."
For an analyst ratings summary and ratings history on 22nd Century Group click here. For more ratings news on 22nd Century Group click here.
Shares of 22nd Century Group closed at $3.18 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Mizuho Starts Sol Gel Technologies Ltd. (SLGL) at Outperform
- Goldman Sachs Assumes Klaviyo Inc (KVYO) at Buy
- JPMorgan Downgrades HCL Technologies (HCLT:IN) to Underweight
Create E-mail Alert Related Categories
Analyst Comments, New CoverageRelated Entities
Cowen & Co, FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share